The current management of early stage @entity978 ( @entity978 ) is usually based on clinical staging, combined modality therapy and the use of less toxic chemotherapy regimens. This approach entails high cure rates, while ensures less long term @entity137 with avoidance of laparotomy. The aim of this study was to assess the efficacy of a brief course of @entity632 , @entity1732 , @entity5713 , @entity2699 (ABVD) chemotherapy followed by limited field radiotherapy (RT) in favorable clinical stage (CS) I and IIA @entity978 . Forty @entity1 , aged 17-68 (median 34) years, with favorable CS I and IIA @entity978 , without bulky mediastinal disease, have been treated with 4-6 (median 4) cycles of ABVD plus limited field RT. Twenty seven (67%) @entity1 received 4 cycles of chemotherapy, while 13 received 5-6 cycles. Thirty five (87%) @entity1 received limited field RT with dose 24-36 Gy and five (13%) received extended field with 36-46 Gy. All @entity1 responded completely to chemotherapy. One @entity1 experienced a relapse two months after the end of therapy. All @entity1 are alive; 39 in continuous complete remission. With a median follow-up period of 44 months (range 18-101) the actuarial overall and progress free survival was 100 and 97% at 5 years. We did not observe any case of @entity1778 or solid @entity5 . @entity358 was mild in cases of mediastinal irradiation. Considering the short follow-up time and the small number of @entity1 , the combination of a brief course of ABVD plus regional RT is a very efficacious treatment of favorable CS I and IIA @entity978 with mild @entity137 . However, long term survival data are needed, which could give confident answers regarding the risk of late therapy related complications, particularly second @entity5 .

Treatment of early clinically staged XXXX with a combination of ABVD chemotherapy plus limited field radiotherapy.

@entity632 :: ('MESH:D004317', 'Chemical') :: ['Adriamycin'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity2699 :: ('MESH:D003606', 'Chemical') :: ['Dacarbazine'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignancies'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['secondary leukemia'] @entity358 :: ('MESH:D008171', 'Disease') :: ['Pulmonary toxicity'] @entity1732 :: ('MESH:D001761', 'Chemical') :: ['Bleomycin'] @entity978 :: ('MESH:D006689', 'Disease') :: ['HD', "Hodgkin's disease"] @entity5713 :: ('MESH:D014747', 'Chemical') :: ['Vinblastine']
@entity978 :: (MESH:D006689,Disease) :: ['Hodgkin's disease']
